Abeona Therapeutics News

Cantor Fitzgerald Inc.: The Abeona Therapeutics (ABEO.US) rating was reaffirmed and adjusted from an increase in holdings to an increase rating, with a target price of $36.00.

Zhitong FinanceApr 23 20:50

Abeona Therapeutics Analyst Ratings

BenzingaApr 23 20:45

Abeona Therapeutics Analyst Ratings

BenzingaAug 24, 2023 23:49

Abeona Therapeutics Analyst Ratings

BenzingaJul 13, 2023 20:55

Alliance Global Partners Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

BenzingaMay 24, 2023 23:58

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (ASND) and Abeona Therapeutics (ABEO)

TipRanksNov 15, 2022 04:50

SVB Leerink Maintains Market Perform on Abeona Therapeutics, Raises Price Target to $6

Benzinga Real-time NewsNov 15, 2022 03:06

Cantor Fitzgerald Adjusts Price Target on Abeona Therapeutics to $40 From $22, Maintains Overweight Rating

MT NewswiresNov 9, 2022 00:47

Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $40

Benzinga Real-time NewsNov 9, 2022 00:36

Abeona Therapeutics (ABEO) Gets a Hold From SVB Securities

TipRanksNov 7, 2022 11:30